[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@sanofi Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::35846368.png) @sanofi Sanofi

Sanofi posts on X about people with, $7846t, has been, france the most. They currently have XXXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::35846368/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::35846368/c:line/m:interactions.svg)

- X Week XXXXX +210%
- X Month XXXXXX +12%
- X Months XXXXXX +135%
- X Year XXXXXX -XX%

### Mentions: X [#](/creator/twitter::35846368/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::35846368/c:line/m:posts_active.svg)

- X Week X +60%
- X Month XX +13%
- X Months XX +23%
- X Year XX +9.80%

### Followers: XXXXXXX [#](/creator/twitter::35846368/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::35846368/c:line/m:followers.svg)

- X Week XXXXXXX +0.02%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXX -XXXX%
- X Year XXXXXXX -XXXX%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::35846368/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::35846368/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::35846368/influence)
---

**Social category influence**
[stocks](/list/stocks)  XX% [countries](/list/countries)  XX%

**Social topic influence**
[people with](/topic/people-with) #556, [$7846t](/topic/$7846t) 10%, [has been](/topic/has-been) 10%, [france](/topic/france) 10%, [singapore](/topic/singapore) 10%, [faster](/topic/faster) XX%

**Top accounts mentioned or mentioned by**
[@smallcapbob2](/creator/undefined) [@klln349312](/creator/undefined) [@regeneron](/creator/undefined) [@mhdalliance](/creator/undefined) [@karen_kelowna](/creator/undefined) [@ncdalliance](/creator/undefined) [@sankarnara90096](/creator/undefined) [@garyselfcare](/creator/undefined) [@thepharmaletter](/creator/undefined) [@qicprogramme](/creator/undefined) [@bkanderson767](/creator/undefined) [@wethenorth47](/creator/undefined) [@buboon09](/creator/undefined) [@oranomed](/creator/undefined) [@mu_thur6000](/creator/undefined) [@nonzerosumgain](/creator/undefined) [@kellrvoice3](/creator/undefined) [@biff234523](/creator/undefined) [@pulmapp](/creator/undefined) [@bioworld](/creator/undefined)
### Top Social Posts [#](/creator/twitter::35846368/posts)
---
Top posts by engagements in the last XX hours

"We have presented Phase X data at #ESMO25 supporting the potential of our investigational therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read more CC: @OranoMed @RadioMedix"  
[X Link](https://x.com/sanofi/status/1980222306065711164) [@sanofi](/creator/x/sanofi) 2025-10-20T10:39Z 148.8K followers, XXX engagements


"#NEWS: The @US_FDA accepted the filing of our sBLA for recently diagnosed stage X #Type1Diabetes for expedited review through the FDA Commissioners National Priority Voucher (CNPV) pilot program. Learn more"  
[X Link](https://x.com/sanofi/status/1980242597198090492) [@sanofi](/creator/x/sanofi) 2025-10-20T12:00Z 148.8K followers, 1307 engagements


"#NEWS: FLUNITY-HD study in @TheLancet assessed the effectiveness of our high-dose #influenza vaccine against hospitalizations in 65+ vs standard-dose. Learn more"  
[X Link](https://x.com/sanofi/status/1980138861973151851) [@sanofi](/creator/x/sanofi) 2025-10-20T05:07Z 148.8K followers, 2936 engagements


"The CHMP recommended the approval of our medicine for certain adults and adolescents in the EU with #ChronicSpontaneousUrticaria (CSU) potentially providing a new option for people with this debilitating skin disease. CC: @Regeneron"  
[X Link](https://x.com/sanofi/status/1969996081179263152) [@sanofi](/creator/x/sanofi) 2025-09-22T05:24Z 148.8K followers, 1461 engagements


"Data from our phase X head-to-head study in people with chronic rhinosinusitis with nasal polyps (#CRSwNP) and coexisting asthma has been published in @LancetRespirMed. Learn more about the findings. CC: @Regeneron"  
[X Link](https://x.com/sanofi/status/1972179469252038766) [@sanofi](/creator/x/sanofi) 2025-09-28T06:00Z 148.8K followers, 1539 engagements


"#NEWS: The @EMA_News CHMP has recommended the approval of our new treatment for adults with immune thrombocytopenia (#ITP) reinforcing our commitment to advance scientific innovation that addresses unmet patient needs in #RareDiseases. Learn more"  
[X Link](https://x.com/sanofi/status/1979155328177704996) [@sanofi](/creator/x/sanofi) 2025-10-17T11:59Z 148.8K followers, XXX engagements


"#NEWS: Results from a phase X study evaluating a new investigational therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrated potential benefit in a rare and difficult-to-treat cancer. Click here for more information CC: @OranoMed"  
[X Link](https://x.com/sanofi/status/1975790409109721258) [@sanofi](/creator/x/sanofi) 2025-10-08T05:08Z 148.8K followers, 1529 engagements


"Our Modulus facilities were named as one of @TIME Magazine 2025 Best Inventions in Medical & Healthcare These next-generation sites in France and Singapore produce multiple vaccines and biologics simultaneously bringing life-changing treatments to patients faster than ever"  
[X Link](https://x.com/sanofi/status/1976300630164767103) [@sanofi](/creator/x/sanofi) 2025-10-09T14:56Z 148.8K followers, 2088 engagements


"Results from a phase X study evaluating an investigational treatment for alpha-1 antitrypsin deficiency (#AATD) achieved all primary and key secondary endpoints. Read our press release to learn more about our research on this #RareDisease"  
[X Link](https://x.com/sanofi/status/1980863163630600221) [@sanofi](/creator/x/sanofi) 2025-10-22T05:05Z 148.8K followers, XXX engagements